Earnings Results
Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings results on July 30, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.07, beating the consensus estimate of $-0.41 by $0.34 per share. Revenue came in at $103.5M, beating the estimate of $86.6M.
Company Overview
Castle Biosciences's stock moved following the earnings release. The stock currently trades at $26.79 with a market capitalization of $1.1B.
Castle Biosciences's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 83% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Castle Biosciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Castle Biosciences Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q2 (Jul 2026) | $-0.07 | $-0.41 | +82.9% |
| Q1 (May 2026) | $-0.49 | $-0.50 | +2.0% |
| Q4 (Feb 2026) | $-0.08 | $-0.24 | +66.7% |
Related Tools: Earnings Calendar | View CSTL Stock Page
Frequently Asked Questions
When does Castle Biosciences report earnings?
Check the latest earnings dates on our CSTL earnings page or the Earnings Calendar.
Did CSTL beat earnings estimates?
See the full Q2 results including EPS actual vs estimate on our CSTL earnings page.